Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.0152W HIGH $52.50
Volume
6.70 K
Value Traded
293.35 K
Short % Float
5.06%
Days to Cover
1.7
-11.98%Week
-0.95%1 Month
-43.73%3 Month
-66.29%6 Month
-96.34%5 Year
-99.31%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.09 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
813.13 K
Float Shares
620.00 K
Insiders
3.57%
Institutions
4.55%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TRIB Catalyst Timeline
Dated clinical, regulatory and corporate events for Trinity Biotech plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Trinity Biotech plc
5Total events
2Upcoming
2Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T1NDA Submission
Subscribe to view catalyst details
Event history 3
▲Full ResultsCGMClinical Data
Clinical study results demonstrating CGM+ capability to identify nocturnal compression-related false low glucose events
diabetessource ↗
Past FDA Catalysts and PDUFA Decisions
How TRIB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Trinity Biotech plc is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every TRIB program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TRIB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.1 % | 1.86 M | 1.79 M |
TRIB Institutional Ownership Trends
TRIB Short Interest
Shares sold short, counted twice a month.
5.06%
Short % of Float
of tradable shares sold short
31.4K
Shares Sold Short
+75.5% vs prior count
1.7 Low
Days to Cover
trading days of normal volume to buy every short share back
18.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TRIB ranks across every disease it competes in
Competitive Position is a premium feature
See how TRIB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTRIB News
TRIB▼ -11.7%on this news
Trinity Biotech’s Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure
Trinity Biotech's subsidiary, Trinovium, has signed a contract with Red Team Investments to supply advanced liquid cooling solutions for AI data centers. This partnership aims to develop direct-to-chip cooling technologies, addressing the increasing thermal management demands due to rising AI workloads. The collaboration is expected to provide valuable operational data for product refinement and commercialization.
Read more →TRIBTrinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
Trinity Biotech plc has provided an update on its diagnostics business, highlighting progress in its transformation strategy, including the appointment of a new commercial leader in Europe and advancements in its diagnostic pipeline. The company has expanded its PrePsia™ patent portfolio and is rolling out upgraded HbA1c technology. However, it faces challenges with Nasdaq compliance due to market value concerns.
Read more →TRIBTrinity Biotech’s Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure
Trinity Biotech's subsidiary, Trinovium, has partnered with Echelon Data Centres to develop advanced liquid cooling solutions tailored for AI and high-density computing environments. This collaboration aims to leverage Trinovium's expertise in fluid manufacturing alongside Echelon's data center infrastructure knowledge. The market for liquid cooling is expected to see significant growth, indicating a promising future for this partnership.
Read more →TRIBTrinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement
Trinity Biotech has secured an additional $7.0 million investment from Perceptive Advisors, enhancing its financial position as it continues to focus on strategic growth initiatives. The company has also regained compliance with Nasdaq's minimum bid price requirement, marking a significant milestone. This investment will support advancements in its CGM+ platform and other diagnostic solutions.
Read more →TRIB▼ -15.4%on this news
Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology
Trinity Biotech has partnered with Latch Medical to advance biosensor-guided precision drug delivery solutions. This collaboration combines Trinity's CGM+ wearable biosensor platform with Latch's intradermal drug delivery technology to develop innovative therapies for metabolic conditions. The partnership aims to create personalized treatment approaches leveraging real-time metabolic data.
Read more →TRIB▼ -15.4%on this newsshared move
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
Trinity Biotech plc plans to change the ADS ratio from 1:20 to 1:600, effectively a reverse split. This move aims to comply with Nasdaq's minimum bid price and attract more investors. The change will take effect on July 24, 2026, with no fractional ADSs issued. The company anticipates a proportional increase in ADS price but cannot guarantee it.
Read more →TRIB▲ +5.5%on this news
New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
Trinity Biotech announced positive clinical trial results for its CGM+ wearable biosensor, which effectively distinguishes between true and false low glucose readings. The technology addresses a common limitation in conventional continuous glucose monitoring systems, providing additional physiological context. This advancement is expected to enhance user experience and strengthen Trinity's market position in the $15 billion global CGM market.
Read more →TRIB▼ -6.9%on this newsshared move
Trinity Biotech’s Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling
Trinity Biotech's subsidiary, Trinovium, has secured Silver Membership in the Open Compute Project, marking a significant milestone in its entry into the AI data center market. This membership will facilitate engagement with industry leaders and support the development of advanced liquid cooling solutions. The liquid cooling market is expected to grow substantially, providing Trinovium with opportunities for product validation and customer access.
Read more →TRIB▲ +15.9%on this newsshared move
Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
Trinity Biotech has announced the termination of its Standby Equity Purchase Agreement with Yorkville Advisors. The decision reflects the company's current financing strategy, indicating a shift away from utilizing the equity line of credit facility. The announcement includes forward-looking statements regarding the company's financial resources and potential growth, amidst various operational risks.
Read more →TRIB▼ -39%on this news
Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market
Trinity Biotech has launched Trinovium, a subsidiary focused on advanced liquid cooling solutions for AI data centers. This initiative aims to address the growing need for reliable cooling systems as AI workloads increase. The liquid cooling market is expected to grow significantly, providing Trinity with a capital-efficient entry into this expanding sector. The company will utilize its existing manufacturing capabilities to support Trinovium's operations.
Read more →TRIB▼ -15.8%on this news
Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results
Trinity Biotech has received substantial orders for over 2 million TrinScreen HIV tests, reinforcing demand in global health markets. The company reported a 43% revenue increase in Q1 2026, with significant improvements in gross margin. Despite a net loss, the company is executing its Comprehensive Transformation Plan to enhance profitability and scalability.
Read more →TRIBTrinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations
Trinity Biotech plc has appointed Jerry Lydon as the new lead for North America Commercial Operations, aiming to strengthen its revenue and profitability following a Comprehensive Transformation Plan. The company reported its Q4 2025 financial results, revealing revenue in line with prior forecasts but also a decrease compared to the previous year due to various operational challenges. Despite a few improvements, including better gross margins and the recognition of its Premier HbA1c 9210 platform, the company faces financial hurdles, indicated by increased net losses and declining revenues.
Read more →TRIB▼ -5.1%on this news
Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test
Trinity Biotech announced successful clinical results for its enhanced EpiCapture prostate cancer test, which uses machine learning to improve risk prediction accuracy. The test demonstrated an impressive clinical accuracy of 85% in a study involving 750 diverse patient samples. The company plans to commercialize the test through its New York laboratory, marking a significant step into precision oncology.
Read more →TRIB▼ -7%on this news· ran to -19% by day 3shared move
Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren’s Syndrome
Trinity Biotech has partnered with the University at Buffalo to develop and commercialize biomarkers for Sjögren's Syndrome, a commonly underdiagnosed autoimmune disease. This collaboration aims to enhance diagnostic accuracy and speed, addressing significant unmet clinical needs. The initiative is part of Trinity's strategy to expand its specialty diagnostic offerings in the U.S. market.
Read more →TRIBTrinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System
Trinity Biotech has begun the rollout of its next-generation HbA1c column system in Brazil after receiving regulatory approval. This system, part of the Premier Hb9210 platform, has achieved the prestigious IFCC Gold classification for 2026, highlighting its clinical accuracy. The company aims to address the growing diabetes population in Brazil, which necessitates reliable testing technologies. Additionally, the appointment of Bruna Gigliotti to lead the Brazilian commercial organization is expected to enhance market penetration.
Read more →TRIB▲ +10%on this news· ran to +24% by day 3shared move
Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program
Trinity Biotech plc announced that its senior executives will attend the ATTD 2026 conference in Barcelona to foster collaborations for its next-generation Continuous Glucose Monitoring (CGM) platform, CGM+. Highlighting positive clinical performance data, the company sees this as a pivotal step towards commercialization, preparing for a major clinical trial. The conference provides an opportunity for the company to engage with potential partners in research and distribution as they move forward with their innovative diabetes management solutions.
Read more →TRIB▼ -6.7%on this newsshared move
Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform
Trinity Biotech has announced major advancements in its CGM+ platform, which enhances glucose measurement accuracy and aims for a pivotal clinical trial initiation in 2026. The updated device, incorporating advanced electronics and AI-native analytics, seeks to improve sustainability and reduce costs in glucose monitoring. The company is positioned to capture significant market growth in the $15 billion continuous glucose monitoring space, leveraging its cutting-edge technology. The developments are anticipated to contribute substantially to the company's growth and presence in the healthcare market.
Read more →TRIB▼ -6.7%on this newsshared move
Trinity Biotech Provides Business and Trading Update
Trinity Biotech plc has provided an update on its trading activities for Q4 2025, projecting revenues between $11.5 million and $12.5 million, down from $15.9 million in Q4 2024. This decrease is attributed to disruptions in the global HIV testing market and the transition to outsourced manufacturing under its Comprehensive Transformation Plan. The company is focused on advancing commercial efforts in HIV testing and diabetes management, while also pursuing regulatory approvals for new products. These moves are part of a broader strategy aimed at long-term profitable growth.
Read more →TRIBTrinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives
Trinity Biotech has entered into a $25 million Standby Equity Purchase Agreement with Yorkville Advisors to enhance its commercialization and R&D efforts. The financing aims to support the company's growth, particularly in HIV testing and the development of its next-generation glucose monitoring platform, CGM+. The company anticipates continued operational progress into 2026.
Read more →TRIBTrinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
Trinity Biotech has received a notice from Nasdaq indicating it no longer meets the minimum market value of publicly held shares, which is set at $15 million. The company has until August 18, 2026, to regain compliance; failure to do so could lead to delisting from the Nasdaq. Although there is a possibility for the company to apply for transfer to the Nasdaq Capital Market, success in an appeal against delisting is not assured. This situation raises concerns regarding Trinity Biotech's operational stability.
Read more →About Trinity Biotech plc
BIOPHARMAWATCH ELITE PLUS
Trade the next TRIB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime